US20100256414A1 - Process for the preparation of chirally pure nateglinide - Google Patents
Process for the preparation of chirally pure nateglinide Download PDFInfo
- Publication number
- US20100256414A1 US20100256414A1 US12/755,572 US75557210A US2010256414A1 US 20100256414 A1 US20100256414 A1 US 20100256414A1 US 75557210 A US75557210 A US 75557210A US 2010256414 A1 US2010256414 A1 US 2010256414A1
- Authority
- US
- United States
- Prior art keywords
- nateglinide
- preparation
- formula
- crystalline modification
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 title claims abstract description 66
- 229960000698 nateglinide Drugs 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 230000008569 process Effects 0.000 title claims abstract description 29
- 230000004048 modification Effects 0.000 claims abstract description 55
- 238000012986 modification Methods 0.000 claims abstract description 55
- 239000002253 acid Substances 0.000 claims abstract description 28
- 150000001447 alkali salts Chemical class 0.000 claims abstract description 21
- 239000002585 base Substances 0.000 claims abstract description 11
- OELFLUMRDSZNSF-OFLPRAFFSA-N (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid Chemical compound C1CC(C(C)C)CCC1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-OFLPRAFFSA-N 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 66
- 239000000047 product Substances 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 27
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 24
- 239000012535 impurity Substances 0.000 claims description 21
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 13
- 239000011707 mineral Substances 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 11
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000002844 melting Methods 0.000 claims description 8
- 230000008018 melting Effects 0.000 claims description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- 239000012065 filter cake Substances 0.000 claims description 7
- 239000013078 crystal Substances 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 5
- 238000001237 Raman spectrum Methods 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 238000002329 infrared spectrum Methods 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 238000005406 washing Methods 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 1
- 230000020477 pH reduction Effects 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 239000000126 substance Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- LUSNEIVFFXOKHW-DAWZGUTISA-N methyl (2r)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoate Chemical compound C([C@H](C(=O)OC)NC(=O)C1CCC(CC1)C(C)C)C1=CC=CC=C1 LUSNEIVFFXOKHW-DAWZGUTISA-N 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- LXJXLQQEYHGVEH-SZMVWBNQSA-N CC(C)[C@H]1CC[C@H](C(=O)N[C@@H](C)CC2=CC=CC=C2)CC1 Chemical compound CC(C)[C@H]1CC[C@H](C(=O)N[C@@H](C)CC2=CC=CC=C2)CC1 LXJXLQQEYHGVEH-SZMVWBNQSA-N 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000001069 Raman spectroscopy Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012069 chiral reagent Substances 0.000 description 2
- 150000001924 cycloalkanes Chemical class 0.000 description 2
- YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000006340 racemization Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
Definitions
- the invention relates to N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine (nateglinide) of the formula (I) in the crystalline form “G”, as well as a process for the preparation thereof.
- Another aspect of the invention is a process for the preparation of nateglinide in crystalline form “H” from other crystal modifications having lower melting points. Further the invention provides a process for preparing chirally pure nateglinide
- R is a lower alkyl (C 1 -C 4 ) group or hydrogen, which comprises treating the compound of the formula (II) with a base to yield an alkali salt, then adding an acid in a proper manner to said alkali salt to liberate the product.
- Nateglinide is known as the active ingredient of a composition for treating type 2 diabetes (J. Med. Chem. 32, 1436 (1989)). Also known are the methods for the preparation of the product and two crystalline forms thereof (the unstable form “B”, mp: 127-129° C. and the stable form “H”, mp: 139° C.).
- Another possible purification method is to use a chiral reagent in a calculated amount based on the enantiomeric impurity. This latter method, however, is not profitable on industrial scale since it results in a substantial increase in costs and processing time.
- the aim of the present invention is to provide a process suitable for plant-scale preparation of chirally pure nateglinide with high yield and short reaction time in the crystalline form “H” required for the pharmaceutical composition or to obtain crystalline form “H” from other crystal modifications.
- This process permits crystallization of the product repeatedly from very thin solutions, an operation demanding cost and labor without any certainty of obtaining a product with chiral purity.
- the invention provides a process for the preparation of crystalline modifications of nateglinide of the formula (I), by treating a compound of the formula (II) with a base to yield an alkali salt of the product and liberating the product from said salt, in such a manner that the liberation of the product by an acid is carried out below room temperature, preferably within the temperature range of 0° C. to 20° C. to yield nateglinide in crystalline modification “G”; or above room temperature, preferably within the temperature range of 65° C. to 70° C. to yield nateglinide in crystalline modification “H”.
- the invention also provides a process for the preparation of nateglinide of the formula (I), by treating a compound of the formula (II) with a base to yield an alkali salt of the product and liberating the product from said salt, in such a manner that the liberation of he product is carried out by addition of equivalent amount of a mineral acid in portions, preferably in two portions (selective precipitation), i.e. first less than equimolar amount of the acid is added yielding a mixture of nateglinide and an alkali salt thereof, said mixture is isolated and a further amount of the mineral acid is added to it to give the chirally pure nateglinide.
- the invention provides a process for the preparation of the stable crystalline form “H” from other crystalline modifications having lower melting points.
- nateglinide methyl ester is hydrolysed in an aqueous alkanol at 15-30° C. in the presence of 1-1,5 equivalent, preferably 1,2 equivalent of sodium hydroxide.
- the solution containing the alkali salt obtained is treated with a mineral acid in a first step in an amount calculated with respect to 0.4 to 0.6 equivalents of the ester plus the excess base.
- the mixture of nateglinide and alkali salt thereof so obtained is isolated by filtration, the filter cake is dissolved and the solution is heated to a temperature-in the case of crystalline modification “H” to 65-70° C.-suitable for continuing the liberation of the product with aqueous mineral acid.
- the precipitated product is isolated by filtration and dried at 50-60° C.
- Rearrangement of the crystalline modifications having lower melting points into the stable crystalline modification “H” is carried out without employing aqueous solvents; it is accomplished in alkanes or cycloalkanes, such as n-hexane or n-heptane with short term boiling.
- the base employed in the process may be an alkali hydroxide; preferably sodium hydroxide, potassium hydroxide or lithium hydroxide; most preferably it is sodium hydroxide.
- the mineral acid employed in the process can be hydrochloric acid, sulphuric acid; preferably it is hydrochloric acid.
- the product containing chiral impurity is purified by adding equivalent amount of an alkali hydroxide to it in methanol solution, followed by the selective precipitation described above.
- Chiral purity of the product obtained according to the invention can readily and exactly be determined by HPLC and NMR spectroscopy.
- the ratio of enantiomers in the end-product can be determined without the use of any external chiral auxiliary; evaluation is simply based on distinct 1H-NMR signals brought about by self-recognition of the enantiomers.
- the process according to the invention has the advantage that chirally pure product can be prepared in a simple way with good yield without making several purification steps and any of the crystalline modifications can be obtained; further, by carrying out the product liberation at a suitable temperature, crystalline modification “G” which is easy-to-filter can also be obtained. Since for the preparation of crystalline modification “H” from other crystalline forms having lower melting points a solvent other than a mixture of aqueous and organic solvent is used, recovery of the organic solvent can easily be accomplished, which again, is an advantage.
- FIG. 1 Raman spectrum of the nateglinide crystalline modification “G” of the invention is shown.
- FIG. 2 infra-red spectrum of the nateglinide crystalline modification “G” of the invention is shown.
- Raman spectra of the nateglinide crystalline modification “H”, “B” and “G” are given designated as 1,2 and 3, respectively.
- Nateglinide modification “H” IR: 3315,3065, 3031 2926, 2861,1714, 1650,1541, 1446, 1425, 1292, 1214, 1187, 934,756, 742,700, 558 Raman: 3059, 2935, 2902, 2862, 2844, 1652,1606, 1587,1463, 1443,1337, 1310,1208, 1158, 1080, 1004,950, 884, 82S, 811, 794, 748, 623,494, 408, 263 Nateglinide modification “B”: IR: 3313,3064, 3028, 2934, 2858, 1732, 1706, 1648, 1536, 1446,1386, 1298, 1217, 1178, 1078, 934,755, 702, 569, 498 Raman: 3055, 3040, 2936,2903, 2866, 1735, 1650,1606, 1586, 1462,1442, 1333, 1209,1158, 1081,1004, 911, 880
- Enantiomeric impurity was under the detection limit of HPLC ; total amount of other impurities was below 0.1%.
- the wet substance is transferred into a round bottom flask and was boiled in 513 g (750 ml) of n-heptane with stirring for 1.5 hours.
- the suspension was cooled to 20-25° C. and stirred for 20 minutes at this temperature.
- the product was filtered, washed with 2 ⁇ 100 ml (2 ⁇ 68 g) n-heptane and dried under infra-red lamp at 50 ° C., affording 25.68 g (80.9%) of nateglinide in the crystalline form “H”.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine (nateglinide) in the novel crystalline form “G” and a process for the preparation thereof. A process for the preparation of chirally pure nateglinide by treating a lower alkyl ester thereof with a base to yield an alkali salt and liberating the product from said salt by proper addition of an acid, is also provided. Still another aspect of the invention is a process for the preparation of nateglinide in the crystalline form “H” from other crystalline modifications of nateglinide.
Description
- This application is a division of U.S. patent application Ser. No. 10/564,017 filed 15 May 2006 which is the U.S. National Phase of PCT/HU2004/000073 filed 8 Jul. 2004 with a claim to the priority of Hungarian Patent Application P0302174 filed 10 Jul. 2003.
- The invention relates to N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine (nateglinide) of the formula (I) in the crystalline form “G”, as well as a process for the preparation thereof. Another aspect of the invention is a process for the preparation of nateglinide in crystalline form “H” from other crystal modifications having lower melting points. Further the invention provides a process for preparing chirally pure nateglinide
- from a compound of the formula (II),
- wherein R is a lower alkyl (C1-C4) group or hydrogen, which comprises treating the compound of the formula (II) with a base to yield an alkali salt, then adding an acid in a proper manner to said alkali salt to liberate the product.
- Nateglinide is known as the active ingredient of a composition for treating
type 2 diabetes (J. Med. Chem. 32, 1436 (1989)). Also known are the methods for the preparation of the product and two crystalline forms thereof (the unstable form “B”, mp: 127-129° C. and the stable form “H”, mp: 139° C.). - In J. Med. Chem. (ibid) preparation of the crystalline form “B” is described; in the reaction this product is formed in each case.
- In U.S. Pat. No. 5,488,150 patent preparation of the crystalline form “H” from the unstable crystal modification “B” is disclosed. This rearrangement occurs when modification “B” is kept in an aqueous organic solvent (acetone, acetonitrile or alcohols) under stirring for 24 hours. This process however, has the drawback that the stable modification “H” which is contained in the composition is prepared in a time-consuming additional step. Another disadvantage is that the modification “B” is difficult-to-filter which is a serious problem in an industrial process. Still another drawback is that application of an aqueous system makes recovery of the organic solvent difficult.
- According to J. Med. Chem. (ibid) and U.S. Pat. No. 4,816,484 patent specification the product is obtained by alkaline hydrolysis of the nateglinide methyl ester yielding the corresponding alkali salt, which is turn, is treated with mineral acid to give the product.
- While none of the aforesaid publications makes mention of the optical purity of the product, it can be of fundamental importance in view of the difference in the biological activity of the enantiomers. Therefore, every effort should be taken to minimize the amount of enantiomeric impurity.
- It is known from the chemical literature that the chiral carbon atom present in the a-amino acids and dipeptides is more or less susceptible to racemization. This susceptibility is so expressed that even in the presence of a weak base, such as barium hydroxide (Hoppe-Syler's Z. Physiol. Chem. 33,173 (1901)) or calcium hydroxide racemization takes place resulting in enantiomeric contamination in the nateglinide end-product.
- Reproducing the process described in the U.S. Pat. No. 4,816,484 we have measured 0.2 to 0.3% enantiomeric impurity in the product; this value doesn't meet the tight requirements imposed either by the pharmacopoeia or the health authorities and quality directives, since the acceptable maximum for chiral impurities is 0.1%. Consequently the product prepared by the process mentioned above needs further purification, which could be done by several recrystallization steps from very thin solutions with a rather low (10-20%) yield.
- Another possible purification method is to use a chiral reagent in a calculated amount based on the enantiomeric impurity. This latter method, however, is not profitable on industrial scale since it results in a substantial increase in costs and processing time.
- The aim of the present invention is to provide a process suitable for plant-scale preparation of chirally pure nateglinide with high yield and short reaction time in the crystalline form “H” required for the pharmaceutical composition or to obtain crystalline form “H” from other crystal modifications.
- During our experiments we have surprisingly found that when the nateglinide is liberated from a salt thereof in the presence of a water-miscible organic solvent at a temperature below 20° C., a crystalline modification not known in the art is obtained with an mp of 100-109° C. and with filtration properties which are better than those of the known crystalline modifications. We designate this novel form crystalline modification “G”.
- From the above modification “G” the crystalline form “H” is obtained on heating in an alkane or cycloalkane, such as n-hexane or n-heptane without using any aqueous organic solvent.
- Further we have quite unexpectedly found that when the product liberation either from an alkali salt obtained at the end of the alkaline hydrolysis of the nateglinide alkyl ester, or from an alkali salt of nateglinide containing an enantiomeric impurity, is not carried out in a one-step fashion by adding equivalent amount of a mineral acid, but the acid is added in two portions in such a way that first less than an equimolar amount of the acid is added yielding a mixture of nateglinide and an alkali salt thereof, isolating said mixture and adding a further amount of mineral acid to it, the nateglinide so obtained is chirally pure, i.e. contains no enantiomeric impurity. When nateglinide is prepared from a salt thereof different crystalline modifications can be obtained depending on the reaction temperature.
- It is really surprising that by adding mineral acid to the solution of an alkali salt of a substance it is not the acidic product which is obtained in an amount equivalent to the reagent but an acid-salt-mixture. Also it is surprising that by reacting a nateglinide salt containing an enantiomeric impurity with an achiral acid, a pure product containing no enantiomeric impurity is obtained without adding any chiral reagent/auxiliary.
- This process permits crystallization of the product repeatedly from very thin solutions, an operation demanding cost and labor without any certainty of obtaining a product with chiral purity.
- In our experiments we accomplished also the purification of the nateglinide containing enantiomeric impurity in such a manner that to the product containing the enantiomeric impurity a base is added to form the corresponding salt, and the product liberation from said salt is not done in one-step by adding a mineral acid in equivalent amount, but by adding the acid in two portions in such a way that first less than an equimolar amount of the acid is added yielding a mixture of nateglinide and an alkali salt thereof, said mixture is isolated and a further amount of the mineral acid is added to it to give the chirally pure nateglinide.
- Accordingly the invention provides a process for the preparation of crystalline modifications of nateglinide of the formula (I), by treating a compound of the formula (II) with a base to yield an alkali salt of the product and liberating the product from said salt, in such a manner that the liberation of the product by an acid is carried out below room temperature, preferably within the temperature range of 0° C. to 20° C. to yield nateglinide in crystalline modification “G”; or above room temperature, preferably within the temperature range of 65° C. to 70° C. to yield nateglinide in crystalline modification “H”. Nateglinide in the crystalline form “G”-a modification not known in the art-is also within the scope of the invention.
- The invention also provides a process for the preparation of nateglinide of the formula (I), by treating a compound of the formula (II) with a base to yield an alkali salt of the product and liberating the product from said salt, in such a manner that the liberation of he product is carried out by addition of equivalent amount of a mineral acid in portions, preferably in two portions (selective precipitation), i.e. first less than equimolar amount of the acid is added yielding a mixture of nateglinide and an alkali salt thereof, said mixture is isolated and a further amount of the mineral acid is added to it to give the chirally pure nateglinide.
- Further, the invention provides a process for the preparation of the stable crystalline form “H” from other crystalline modifications having lower melting points.
- According to one embodiment of the invention nateglinide methyl ester is hydrolysed in an aqueous alkanol at 15-30° C. in the presence of 1-1,5 equivalent, preferably 1,2 equivalent of sodium hydroxide. The solution containing the alkali salt obtained is treated with a mineral acid in a first step in an amount calculated with respect to 0.4 to 0.6 equivalents of the ester plus the excess base. The mixture of nateglinide and alkali salt thereof so obtained is isolated by filtration, the filter cake is dissolved and the solution is heated to a temperature-in the case of crystalline modification “H” to 65-70° C.-suitable for continuing the liberation of the product with aqueous mineral acid. The precipitated product is isolated by filtration and dried at 50-60° C.
- When the crystalline modification “G” not known in the art is prepared, liberation of the product is accomplished below 20° C. and the product is dried at 30-35° C. In the case of crystalline modification “B” described in the literature, acidifying is carried out at 30-35° C. and the product is dried at 40-45° C.
- Rearrangement of the crystalline modifications having lower melting points into the stable crystalline modification “H” is carried out without employing aqueous solvents; it is accomplished in alkanes or cycloalkanes, such as n-hexane or n-heptane with short term boiling.
- The base employed in the process may be an alkali hydroxide; preferably sodium hydroxide, potassium hydroxide or lithium hydroxide; most preferably it is sodium hydroxide.
- The mineral acid employed in the process can be hydrochloric acid, sulphuric acid; preferably it is hydrochloric acid.
- The product containing chiral impurity is purified by adding equivalent amount of an alkali hydroxide to it in methanol solution, followed by the selective precipitation described above.
- Chiral purity of the product obtained according to the invention can readily and exactly be determined by HPLC and NMR spectroscopy.
- When the end-product obtained according to our method is dissolved in a suitable solvent mixture (CC14:CD2C12=5:7 v/v) and its NMR spectrum is obtained under the conditions given below, the ratio of enantiomers in the end-product can be determined without the use of any external chiral auxiliary; evaluation is simply based on distinct 1H-NMR signals brought about by self-recognition of the enantiomers.
- The process according to the invention has the advantage that chirally pure product can be prepared in a simple way with good yield without making several purification steps and any of the crystalline modifications can be obtained; further, by carrying out the product liberation at a suitable temperature, crystalline modification “G” which is easy-to-filter can also be obtained. Since for the preparation of crystalline modification “H” from other crystalline forms having lower melting points a solvent other than a mixture of aqueous and organic solvent is used, recovery of the organic solvent can easily be accomplished, which again, is an advantage.
- Attached are four figures showing certain spectra of the different crystalline modifications; namely
- In
FIG. 1 . Raman spectrum of the nateglinide crystalline modification “G” of the invention is shown. - In
FIG. 2 . infra-red spectrum of the nateglinide crystalline modification “G” of the invention is shown. - In
FIG. 3 . infra-red spectra of the nateglinide crystalline modification “H”, “B” and “G” are given designated as 1,2 and 3, respectively. - In
FIG. 4 . Raman spectra of the nateglinide crystalline modification “H”, “B” and “G” are given designated as 1,2 and 3, respectively. - Spectroscopic data of the individual modifications are set out below (ci-') with the intensive bands underlined.
- Nateglinide modification “H”: IR: 3315,3065, 3031 2926, 2861,1714, 1650,1541, 1446, 1425, 1292, 1214, 1187, 934,756, 742,700, 558 Raman: 3059, 2935, 2902, 2862, 2844, 1652,1606, 1587,1463, 1443,1337, 1310,1208, 1158, 1080, 1004,950, 884, 82S, 811, 794, 748, 623,494, 408, 263 Nateglinide modification “B”: IR: 3313,3064, 3028, 2934, 2858, 1732, 1706, 1648, 1536, 1446,1386, 1298, 1217, 1178, 1078, 934,755, 702, 569, 498 Raman: 3055, 3040, 2936,2903, 2866, 1735, 1650,1606, 1586, 1462,1442, 1333, 1209,1158, 1081,1004, 911, 880, 832, 805, 750,732, 623, 577, 499, 474,268 Nateglinide modification “G”: IR: 3313,3064, 3031,2934, 2856, 1763, 1735, 1648, 1614, 1533, 1448, 1386, 1368,1216, 1180, 1113,1081, 934, 750, 700, 574, 491 Raman: 3057,2938, 2868, 1762, 1710, 1651,1606, 1586,1462, 1442,1339, 1207, 1182, 1158, 1085,1004, 949, 885, 822, 793 HPLC conditions for determination of chiral purity: Column: CHIRALCEL OD-RH 150×4.6 mm, 5 ul Eluent: 0.1 M K-hexafluoro-phosphate buffer: methanol=30: 70 Flow rate: 0.3 ml/min Temperature: 40° C. Detection: 214 nm Injected volume: 20 je. 1 Sampling: 1 mg of the product to be tested is dissolved in 5 ml eluent.
- Ratio of the enantiomers is measured by 1H-NMR spectroscopy under the conditions set out below: Working frequency: 500 MHz Solvent: CC14:CD2C12=7:5 v/v Reference:
bCD2C 2=5 32 ppm Temperature: 21.5° C. 22 mg of the end-product were dissolved in the above solvent. 0.7 ml aliquot of the solution was used without filtration for analysis. At 4.8 ppm CW coupling with 10 decibel was employed. From the group of signals in the 3.08-3.17 ppm range the enantiomer ratio is determined by the deconvolution method. - The invention is further illustrated by the following non-limiting examples.
- Into a four-necked 1 1 flask equipped with a swinging blade stirrer, a condenser, a thermometer and a feeding funnel 200 g (250 ml) of methanol and 33.1 g (0.1 mol) of nateglinide methyl ester were added. To the suspension formed 4.8 g (0.12 mol) sodium hydroxide dissolved in 110 ml of water were added dropwise at 20-25° C. while the mixture is cooled with cold water. The reaction mixture was kept at 20-25° C. with stirring for 4 hours causing the suspension to become a solution. After the ester was used up in the reaction the small amount of solids was removed from the solution by filtration. To the filtrate 6.9 g (5. 85 ml; 0.07 mol) of concentrated hydrochloric acid in 5.5 ml of water were dropwise added at 10-15° C. The thick suspension obtained was stirred at 13-18° C. for 30 minutes and then filtered. The filter cake was washed first with 43 g (50 ml) of methanol/water mixture (2:1 v/v; 26.3 g methanol+16.7 g water) then with 200 ml of water. The wet substance was dissolved in 514 g (650 ml) of methanol at 25-30° C., the solution was then cooled to 15-20° C. and 5.5 g (4.7 ml; 0.056 mol) of concentrated hydrochloric acid in 5 ml of water were added so that after the addition the pH of the solution would be between 2 and 3. After further stirring for 10 minutes water of 5° C. temperature was added (750 ml) and the precipitate obtained was stirred for 20 minutes. The product was filtered off, washed with water (200 ml) and dried under infra-red lamp at 30-35° C., yielding 26.3 g (94.4%) of nateglinide in the crystalline modification “G”.
- Mp: 100-109° C. Enantiomeric impurity was under the detection limit of HPLC ; total amount of other impurities was below 0.1%.
- Into a four-necked 1 1 flask equipped with a swinging blade stirrer, a condenser, a thermometer and a feeding funnel 200 g (250 ml) of methanol and 33. 1 g (0.1 mol) of nateglinide methyl ester were added. To the suspension formed 4.8 g (0.12 mol) sodium hydroxide dissolved in 110 ml of water were added dropwise at 20-25° C. while the mixture is cooled with cold water. The reaction mixture was kept at 20-25° C. with stirring for 4 hours causing the suspension to become a solution. After the ester was used up in the reaction the small amount of solids was removed from the solution by filtration. To the filtrate 6.9 g (5.85 ml; 0.07 mol) of concentrated hydrochloric acid in 5.5 ml of water were dropwise added at 10-15° C. The thick suspension obtained was stirred at 13-18° C. for 30 minutes and then filtered. The filter cake was washed first with 43 g (50 ml) of methanol/water mixture (2:1 v/v; 26.3 g methanol+16.7g water) then with 200 ml of water. The wet substance was dissolved in 514 g (650 ml) of methanol at 50-60° C. and at the same temperature 5.5 g (4.7 ml ; 0.056 mol) of concentrated hydrochloric acid in 5 ml of water were added so that after the addition the pH of the solution would be between 2 and 3. After further stirring for 10 minutes water was added (750 ml) at the above temperature and the precipitate obtained was stirred for 20 minutes at the above temperature. The product was filtered off, washed with water (200 ml) and dried under infra-red lamp at 60-70° C., yielding 26.3 g (94.4%) of nateglinide in the crystalline form “H”.
- Mp=138-139° C. Enantiomeric impurity was under the detection limit of HPLC; total amount of other impurities was below 0.1%.
- Into a four-necked 1 1 flask equipped with a swinging blade stirrer, a condenser, a thermometer and a feeding funnel 200 g (250 ml) of methanol and 33.1 g (0.1 mol) of nateglinide methyl ester were added. To the suspension formed 4.8 g (0.12 mol) sodium hydroxide dissolved in 110 ml of water were added dropwise at 20-25° C. while the mixture is cooled with cold water. The reaction mixture was kept at 20-25′C. with stirring for 4 hours causing the suspension to become a solution. After the ester was used up in the reaction the small amount of solids was removed from the solution by filtration. To the filtrate 6.9 g (5.85 ml; 0.07 mol) of concentrated hydrochloric acid in 5.5 ml of water were dropwise added at 10-15° C. The thick suspension obtained was stirred at 13-18° C. for 30 minutes and them filtered. The filter cake was washed first with 43 g (50 ml) of methanol/water mixture (2: 1 v/v; 26.3
g methanol 30 16.7 g water) then with 200 ml of water. The wet substance was dissolved in 514 g (650 ml) of methanol at 25-30° C., the solution was then cooled to 15-20° C. and 5.5 g (4.7 ml; 0.056 mol) of concentrated hydrochloric acid in 5 ml of water were added so that after the addition the pH of the solution would be between 2 and 3. After further stirring for 10 minutes water was added (750 ml) at the above temperature and the precipitate obtained was stirred for 20 minutes. Nateglinide crystals of the “G” modification are filtered and washed with 200 ml of water. - The wet substance is transferred into a round bottom flask and was boiled in 513 g (750 ml) of n-heptane with stirring for 1.5 hours. The suspension was cooled to 20-25° C. and stirred for 20 minutes at this temperature. The product was filtered, washed with 2×100 ml (2×68 g) n-heptane and dried under infra-red lamp at 50 ° C., affording 25.68 g (80.9%) of nateglinide in the crystalline form “H”.
- Mp=139-140° C. Enantiomeric impurity was under the detection limit of HPLC; total amount of other impurities was below 0.1%.
- 6.34 g (0.02 mol) of nateglinide (chiral purity: 98%) were dissolved in 50 ml of methanol. To the solution 0.8 g (0.02 mol) of sodium hydroxide in 22 ml of water were added. To this solution a mixture of 0.83 ml concentrated hydrochloric acid and 1 ml water were added dropwise at 10-15° C. temperature. After 30 minutes of stirring the precipitate was filtered, washed with a mixture of methanol/water 2:1, v/v (25 ml) followed by 50 ml of water. The wet substance was dissolved in methanol (130 ml) and a mixture of 0.83 ml concentrated hydrochloric acid and 1 ml water were added. The mixture was stirred for 10 minutes, 150 ml of water were added and stirring was continued for 20 minutes. The product was filtered, washed, suspended in n-heptane (100 ml) and boiled for 1.5 hours. After cooling the product was filtered and dried at 50° C. giving 4.2 g (66.4%) of nateglinide.
- Mp=138-139° C. Enantiomeric impurity was under the detection limit of HPLC; total amount of other impurities was below 0.1%.
Claims (13)
1-11. (canceled)
12. A process for the preparation of crystalline modification “H” of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine (nateglinide) of the formula (I)
which comprises the steps of:
(a) treating a compound of the formula (II)
to wherein R is a lower (C1-C4) alkyl group or hydrogen, with a base to yield an alkali salt, and
(b) acidifying the alkali salt with an acid, at a temperature above room temperature, to obtain the desired product.
13. The process for the preparation of crystalline modification “H” of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine (nateglinide) according to claim 12 , wherein according to step (a), a water-miscible organic solvent is employed.
14. The process for the preparation of crystalline modification “H” of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine (nateglinide) according to claim 13 , wherein the water-miscible organic solvent is aqueous methanol.
15. The process for the preparation of crystalline modification “H” of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine (nateglinide) according to claim 14 wherein the aqueous methanol is methanol containing 20-50% water by volume.
16. The process for the preparation of crystalline modification “H” of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine (nateglinide) according to claim 12 , wherein according to step (b) the acidification temperature is in the temperature range of 65° C. to 70° C.
17. A process for the preparation of nateglinide in the crystalline modification “H” form, which comprises the step of
boiling another crystalline modification of nateglinide having a lower melting point or a mixture of such modifications in an alkane, for a time sufficient to provide the nateglinide in the stable “H” crystalline form.
18. The process for the preparation of nateglinide in the crystalline modification “H” form defined in claim 17 wherein the alkane is n-hexane or n-heptane.
19. The process for the preparation of nateglinide in the crystalline modification “H” form defined in claim 17 wherein, the crystalline modification of nateglinide having a lower melting point is crystalline modification “G” form having the following characteristics:
(a) a melting point of 100 to 109° C.;
(b) an infra-red spectrum with intensive bands at 1763, 1735, 1614, 1533, 1180, 750, 574 and 491 cm−1; and
(c) a Raman spectrum with intensive bands at 1762, 1710, 1182 and 822 cm−1, is employed as starting material.
20. A process for the preparation of nateglinide in the crystalline modification “H” form, which comprises the steps of:
(a) treating a compound of the formula (II)
wherein R is a lower (C1-C4) alkyl group or hydrogen, with a base at 20 to 25° C. to yield an alkali salt;
(b) liberating the product of the Formula (I) from the acid salt with an acid, wherein the acidic liberation of the product is carried out by acidifying the alkali salt in a temperature range of 10 to 15° C. with a first portion of acid to form a suspension, which is then stirred at 13 to 18° C. for 30 minutes, filtered to form a filter cake, washing the filter cake with a methanol/water mixture and then water, dissolving the filter cake in methanol at 25 to 30° C. to form a solution, cooling the solution to 15° C., and again acidifying the solution so that after acidifying the solution again, the pH of the solution is 2 to 3, stirring the solution and adding water at a temperature of 5° C. to the solution to obtain a precipitate, and drying the precipitate at 30 to 35° C. to obtain the crystal modification “G:” form product having the following characteristics:
(i) a melting point of 100 to 109° C.;
(ii) an infra-red spectrum with intensive bands at 1763, 1735, 1614, 1533, 1180, 750, 574 and 491 cm−1; and
(iii) a Raman spectrum with intensive bands at 1762, 1710, 1182 and 822 cm−1; and
(c) boiling the crystal modification “G” Form in an alkane for a time sufficient to provide the nateglinide in the stable “H” crystalline form.
21. The process for the preparation of nateglinide in the crystalline modification “H” form defined in claim 20 wherein according to step (c) the alkane is n-hexane or n-heptane.
22. A process for the preparation of chirally pure N-(trans-4-isopropylcyclohexyl-carbonyl)-D-phenylalanine (nateglinide) of the formula (I)
from a corresponding compound of the Formula (II) that is less chirally pure,
wherein R is a lower (C1-C4) alkyl group or hydrogen, which comprises the steps of
(a) treating the less chirally pure compound of the Formula (II) with a base to yield an alkali salt,
(b) liberating the chirally pure compound of the Formula (I) from the salt with a mineral acid, wherein the acidic liberation of the compound of the Formula (I) is accomplished by adding the acid to the alkali salt in two portions in such a way that the first time less than equimolar amount of the acid is added to yield a mixture of nateglinide and an alkali salt thereof, the mixture is isolated and a further amount of mineral acid is added to the mixture;
(c) filtering and washing the mixture containing the compound of the Formula (I); and
(d) boiling the mixture in an alkane to obtain the chirally pure compound of the Formula (I) having an enantiomeric impurity level of below 0.1%.
23. The process for the preparation of chirally pure N-(trans-4-isopropylcyclohexyl-carbonyl)-D-phenylalanine (nateglinide) of the formula (I) defined in claim 22 wherein according to step (d) the alkane is n-heptane and the boiling is carried out at 150° C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/755,572 US20100256414A1 (en) | 2003-07-10 | 2010-04-07 | Process for the preparation of chirally pure nateglinide |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0302174A HU227073B1 (en) | 2003-07-10 | 2003-07-10 | Process for the preparation of chirally pure n-(trans-4-isopropyl-cyclohexylcarbonyl)-d-phenyl-alanine (nateglinide) and it's crystalline forms and the cristalline form g |
| HUP0302174 | 2003-07-10 | ||
| US10/564,017 US7767847B2 (en) | 2003-07-10 | 2004-07-08 | Process for the preparation of chirally pure N-(trans-4-is) |
| PCT/HU2004/000073 WO2005005373A1 (en) | 2003-07-10 | 2004-07-08 | A process for the preparation of chirally pure n-(trans-4-isopropyl-cyclohexylcarbonyl)-d-phenylalanine and crystalline modifications thereof |
| US12/755,572 US20100256414A1 (en) | 2003-07-10 | 2010-04-07 | Process for the preparation of chirally pure nateglinide |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/HU2004/000073 Division WO2005005373A1 (en) | 2003-07-10 | 2004-07-08 | A process for the preparation of chirally pure n-(trans-4-isopropyl-cyclohexylcarbonyl)-d-phenylalanine and crystalline modifications thereof |
| US11/564,017 Division US8240641B2 (en) | 2005-11-28 | 2006-11-28 | Isolated axial support strut for supporting an axial load and axial support strut isolator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20100256414A1 true US20100256414A1 (en) | 2010-10-07 |
Family
ID=90001695
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/564,017 Expired - Fee Related US7767847B2 (en) | 2003-07-10 | 2004-07-08 | Process for the preparation of chirally pure N-(trans-4-is) |
| US12/755,572 Abandoned US20100256414A1 (en) | 2003-07-10 | 2010-04-07 | Process for the preparation of chirally pure nateglinide |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/564,017 Expired - Fee Related US7767847B2 (en) | 2003-07-10 | 2004-07-08 | Process for the preparation of chirally pure N-(trans-4-is) |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7767847B2 (en) |
| EP (3) | EP2264001A1 (en) |
| JP (2) | JP2007526890A (en) |
| EA (3) | EA011409B1 (en) |
| HU (1) | HU227073B1 (en) |
| RS (1) | RS20050980A (en) |
| WO (1) | WO2005005373A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1616886A4 (en) * | 2003-02-18 | 2006-06-14 | Konishi Co Ltd | Curing resin, method for producing same and curing resin composition |
| HU227073B1 (en) * | 2003-07-10 | 2010-06-28 | Richter Gedeon Nyrt | Process for the preparation of chirally pure n-(trans-4-isopropyl-cyclohexylcarbonyl)-d-phenyl-alanine (nateglinide) and it's crystalline forms and the cristalline form g |
| AU2011266820A1 (en) | 2010-06-14 | 2013-01-24 | Cipla Limited | A process for the preparation of nateglinide |
| CN109369443A (en) * | 2018-11-05 | 2019-02-22 | 扬子江药业集团江苏海慈生物药业有限公司 | A kind of preparation method of new Nateglinide H crystal form |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816484A (en) * | 1985-03-27 | 1989-03-28 | Ajinomoto Co., Inc. | Hypoglycemic agent |
| US5488150A (en) * | 1991-07-30 | 1996-01-30 | Ajinomoto Co., Inc. | Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them |
| US20040077725A1 (en) * | 2002-08-28 | 2004-04-22 | Dr. Reddy's Laboratories Limited | Crystalline form of N-(trans-4-isopropylcyclohexane carbonyl)-D-phenylalanine and process for preparation thereof |
| US6861553B2 (en) * | 2002-07-03 | 2005-03-01 | Teva Pharmaceuticals Industries Ltd. | Process for preparing nateglinide and intermediates thereof |
| US20050090552A1 (en) * | 2002-07-18 | 2005-04-28 | Ronit Yahalomi | Polymorphic forms of nateglinide |
| US20050101672A1 (en) * | 2002-04-15 | 2005-05-12 | Ajinomoto Co., Inc. | Nateglinide crystals |
| US20050165108A1 (en) * | 2002-04-29 | 2005-07-28 | Biocon Ltd | Novel form of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine |
| US20050234129A1 (en) * | 2002-03-11 | 2005-10-20 | Sutton Paul A | Salts of nateglinide |
| US20050256336A1 (en) * | 2002-04-15 | 2005-11-17 | Sutton Paul A | Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine |
| US20060004102A1 (en) * | 2004-05-07 | 2006-01-05 | Shlomit Wizel | Polymorphic forms of nateglinide |
| US7148376B2 (en) * | 2002-07-18 | 2006-12-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US20070043117A1 (en) * | 2003-07-10 | 2007-02-22 | Maria Gazdag | Process for the preparation of chirally pure n-(trans-4-is |
| US20070167523A1 (en) * | 2000-10-18 | 2007-07-19 | Ajinomoto Co. Inc | Methods for producing nateglinide crystals |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050075400A1 (en) * | 2002-07-18 | 2005-04-07 | Ronit Yahalomi | Polymorphic forms of nateglinide |
| US7358390B2 (en) * | 2002-07-18 | 2008-04-15 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7534913B2 (en) * | 2002-07-18 | 2009-05-19 | Teva Pharmaceutica Industries Ltd. | Crystalline form of nateglinide |
| WO2004009532A1 (en) * | 2002-07-18 | 2004-01-29 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| WO2004018408A1 (en) | 2002-08-26 | 2004-03-04 | Glenmark Pharmaceuticals Limited | Synthesis and purification of nateglinide |
| EP1535900B1 (en) | 2003-11-26 | 2006-12-27 | A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.p.A. | Process for the preparation of nateglinide, preferably in b-form |
| WO2007113650A2 (en) | 2006-04-05 | 2007-10-11 | Cadila Pharmaceuticals Limited | A novel and improved process fro the preparation of nateglinide and its polymorph form-h |
| WO2007135533A1 (en) | 2006-05-23 | 2007-11-29 | Aurobindo Pharma Limited | Process for preparing nateglinide b-type crystals |
| WO2008096373A2 (en) | 2007-02-06 | 2008-08-14 | Ind-Swift Laboratories Limited | Process for synthesizing highly pure nateglinide polymorphs |
-
2003
- 2003-07-10 HU HU0302174A patent/HU227073B1/en not_active IP Right Cessation
-
2004
- 2004-07-08 JP JP2006518379A patent/JP2007526890A/en active Pending
- 2004-07-08 EA EA200700896A patent/EA011409B1/en not_active IP Right Cessation
- 2004-07-08 EA EA200600230A patent/EA008883B1/en not_active IP Right Cessation
- 2004-07-08 WO PCT/HU2004/000073 patent/WO2005005373A1/en not_active Ceased
- 2004-07-08 EP EP10181014A patent/EP2264001A1/en not_active Withdrawn
- 2004-07-08 EP EP04743732A patent/EP1651591A1/en not_active Withdrawn
- 2004-07-08 EP EP10181081A patent/EP2264002A1/en not_active Withdrawn
- 2004-07-08 RS YUP-2005/0980A patent/RS20050980A/en unknown
- 2004-07-08 EA EA200700897A patent/EA010569B1/en not_active IP Right Cessation
- 2004-07-08 US US10/564,017 patent/US7767847B2/en not_active Expired - Fee Related
-
2010
- 2010-04-07 US US12/755,572 patent/US20100256414A1/en not_active Abandoned
-
2011
- 2011-01-15 JP JP2011006521A patent/JP2011098975A/en active Pending
Patent Citations (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816484A (en) * | 1985-03-27 | 1989-03-28 | Ajinomoto Co., Inc. | Hypoglycemic agent |
| US5488150A (en) * | 1991-07-30 | 1996-01-30 | Ajinomoto Co., Inc. | Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them |
| US20070167523A1 (en) * | 2000-10-18 | 2007-07-19 | Ajinomoto Co. Inc | Methods for producing nateglinide crystals |
| US20050234129A1 (en) * | 2002-03-11 | 2005-10-20 | Sutton Paul A | Salts of nateglinide |
| US20090143469A1 (en) * | 2002-03-11 | 2009-06-04 | Paul Allen Sutton | Salts of nateglinide |
| US20050256336A1 (en) * | 2002-04-15 | 2005-11-17 | Sutton Paul A | Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine |
| US20050101672A1 (en) * | 2002-04-15 | 2005-05-12 | Ajinomoto Co., Inc. | Nateglinide crystals |
| US20080081927A1 (en) * | 2002-04-15 | 2008-04-03 | Sutton Paul A | Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine |
| US20080194867A1 (en) * | 2002-04-15 | 2008-08-14 | Ajinomoto Co., Inc. | Nateglinide crystals |
| US20080319222A1 (en) * | 2002-04-15 | 2008-12-25 | Sutton Paul A | Crystal forms of N- (trans-4-isopropylctyclohexylcarbonyl) -D-phenylalanine |
| US20050165108A1 (en) * | 2002-04-29 | 2005-07-28 | Biocon Ltd | Novel form of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine |
| US7314955B2 (en) * | 2002-04-29 | 2008-01-01 | Biocon Limited | Form of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine |
| US6861553B2 (en) * | 2002-07-03 | 2005-03-01 | Teva Pharmaceuticals Industries Ltd. | Process for preparing nateglinide and intermediates thereof |
| US20050090552A1 (en) * | 2002-07-18 | 2005-04-28 | Ronit Yahalomi | Polymorphic forms of nateglinide |
| US7148376B2 (en) * | 2002-07-18 | 2006-12-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US20040077725A1 (en) * | 2002-08-28 | 2004-04-22 | Dr. Reddy's Laboratories Limited | Crystalline form of N-(trans-4-isopropylcyclohexane carbonyl)-D-phenylalanine and process for preparation thereof |
| US20070043117A1 (en) * | 2003-07-10 | 2007-02-22 | Maria Gazdag | Process for the preparation of chirally pure n-(trans-4-is |
| US20060004102A1 (en) * | 2004-05-07 | 2006-01-05 | Shlomit Wizel | Polymorphic forms of nateglinide |
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0302174A2 (en) | 2005-07-28 |
| US7767847B2 (en) | 2010-08-03 |
| JP2007526890A (en) | 2007-09-20 |
| EA200600230A1 (en) | 2006-06-30 |
| EP1651591A1 (en) | 2006-05-03 |
| EA008883B1 (en) | 2007-08-31 |
| EA200700896A1 (en) | 2007-10-26 |
| EA200700897A1 (en) | 2007-10-26 |
| EP2264002A1 (en) | 2010-12-22 |
| HUP0302174D0 (en) | 2003-09-29 |
| HU227073B1 (en) | 2010-06-28 |
| US20070043117A1 (en) | 2007-02-22 |
| RS20050980A (en) | 2008-04-04 |
| EA011409B1 (en) | 2009-02-27 |
| WO2005005373A1 (en) | 2005-01-20 |
| JP2011098975A (en) | 2011-05-19 |
| EP2264001A1 (en) | 2010-12-22 |
| EA010569B1 (en) | 2008-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2839344B2 (en) | Method for producing cyclic amino acid and intermediate thereof | |
| RU2273629C2 (en) | Methods for preparing nateglinide crystals | |
| US20100256414A1 (en) | Process for the preparation of chirally pure nateglinide | |
| WO2004005241A1 (en) | Process for producing optically active amide | |
| JP2773587B2 (en) | Process for producing O, O'-diacyltartaric anhydride | |
| JP2518014B2 (en) | Method for purifying α-substituted acetic acid | |
| JP4029992B2 (en) | Production of tartranic acid | |
| US4945181A (en) | Method for resolution of racemic thiamphenicol precursors and intermediates therefor | |
| US4709082A (en) | 2-phenylpropionic acid esters, method for optical resolution thereof and optically active substance thereof | |
| EP1341762A1 (en) | Process for resolving racemic mixtures of piperidine derivatives | |
| JP3640319B2 (en) | Method for producing benzamide derivative | |
| JPH06340599A (en) | Production of optically active 2-aminolactic acid | |
| KR101170192B1 (en) | One-pot process for producing 1,2-benzisoxazole-3-methanesulfonamide | |
| US4734509A (en) | Preparation of 4(5)-hydroxymethyl-5(4)-methylimidazole | |
| WO1990008126A1 (en) | Resolution process | |
| EP0976733A1 (en) | Process for producing 1-chlorocarbonyl-4-piperidinopiperidine or hydrochloride thereof | |
| JP3316917B2 (en) | New phenylalanine salt crystals and their production | |
| JP2773627B2 (en) | Process for producing O, O'-diacyltartaric anhydride | |
| CH637967A5 (en) | ADDITION PRODUCT OF N, N-DIMETHYLACETAMIDE AND A DERIVATIVE OF A CEPHEM-4-CARBOXYLIC ACID AND PROCESS FOR ITS PREPARATION. | |
| EP0621260B1 (en) | Process for producing N,N-disubstituted p-phenylenediamine derivative sulphate | |
| HU207709B (en) | Process for producing n-/n-propyl/-n-/2-/2,4,6-trichloro-phenoxy/-ethyl/-amine | |
| US20040039206A1 (en) | Process for resolving racemic mixtures of piperidine derivatives | |
| US6953859B2 (en) | Production process for 5-alkyl-oxazolidin-2,4-dione | |
| HU227071B1 (en) | Process for the preparation of chirally pure nateglinide | |
| JPH04108766A (en) | Production of optically active 1-methyl-3-phenylpropylamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |